Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04432532 | Neuroendocrine and Adrenal Tumors(NETAT) | withdrawn | — | 0 | University of PennsylvaniaOTHER | 0 | Feb 10, 2025 | clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT04614766 | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors(SPORE-3) | withdrawn | Phase 1 / Phase 2 | 0 | David BushnellOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT00657332 | Clinical and Pathologic Studies in Neuroendocrine Tumors | withdrawn | — | 0 | Stanford UniversityOTHER | 0 | Nov 28, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03623984 | Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers | withdrawn | Early Phase 1 | 0 | University of Alabama at BirminghamOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT04276597 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.(PUTNET) | withdrawn | Phase 2 | 0 | Excel Diagnostics and Nuclear Oncology CenterOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT04915144 | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | withdrawn | Phase 2 | 0 | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04713202 | Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl(NET-PACS) | withdrawn | Phase 2 | 0 | Chandrikha ChandrasekharaOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT04831567 | Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors(MIBNET) | withdrawn | Phase 2 | 0 | AC Camargo Cancer CenterOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT04672876 | Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 0 | Dec 17, 2021 | clinicaltrials |
| NCT04085081 | Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Aug 12, 2021 | clinicaltrials |
| NCT03923257 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | withdrawn | Phase 1 / Phase 2 | 0 | Sue O'DorisioOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT03053284 | Pasireotide in Hyperinsulinemic Hypoglycemia | withdrawn | Phase 2 | 0 | Montefiore Medical CenterOTHER | 0 | May 14, 2021 | clinicaltrials |
| NCT04034745 | Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain | withdrawn | — | 0 | Andrew Hendifar, MDOTHER | 0 | Dec 30, 2020 | clinicaltrials |
| NCT04065165 | Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome(TELEFIRST) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT02882503 | Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic Tumors | withdrawn | N/A | 0 | National Taiwan University HospitalOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT03057509 | A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT01048086 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | withdrawn | Phase 2 | 0 | University of IowaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01860742 | Randomized Phase III of PRRT Versus Interferon(CASTOR) | withdrawn | Phase 3 | 0 | Jules Bordet InstituteOTHER | 1 | Apr 5, 2016 | clinicaltrials |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Feb 10, 2025source: clinicaltrials